title: Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeloma: use of "progression-free survival 2" as a clinical trial end-point.
authors.affiliation: University of Athens School of Medicine, Greece mdimop@med.uoa.gr.
authors.forename: Meletios A
authors.initials: MA
authors.lastname: Dimopoulos
authors.affiliation: Sapienza University of Rome, Italy.
authors.forename: Maria T
authors.initials: MT
authors.lastname: Petrucci
authors.affiliation: Sapienza University of Rome, Italy.
authors.forename: Robin
authors.initials: R
authors.lastname: Foà
authors.affiliation: Frankston Hospital, Monash University, Victoria, Australia.
authors.forename: John
authors.initials: J
authors.lastname: Catalano
authors.affiliation: University of Münster, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Kropff
authors.affiliation: University of Athens School of Medicine, Greece.
authors.forename: Evangelos
authors.initials: E
authors.lastname: Terpos
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Jingshan
authors.initials: J
authors.lastname: Zhang
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Lara
authors.initials: L
authors.lastname: Grote
authors.affiliation: Celgene Corporation, Summit, NJ, USA.
authors.forename: Christian
authors.initials: C
authors.lastname: Jacques
authors.affiliation: University of Turin, Italy.
authors.forename: Antonio
authors.initials: A
authors.lastname: Palumbo
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D018572:Disease-Free Survival; D006801:Humans; D060046:Maintenance Chemotherapy; D009101:Multiple Myeloma / Q000175:diagnosis / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome
keywords: MM-015; PFS2; lenalidomide; maintenance; newly diagnosed multiple myeloma (NDMM)
references.citation: J Clin Oncol. 2015 Oct 20;33(30):3459-66
references.pmid: 26282661
references.citation: J Clin Oncol. 2014 Mar 1;32(7):634-40
references.pmid: 24449241
references.citation: N Engl J Med. 2012 May 10;366(19):1782-91
references.pmid: 22571202
references.citation: Blood. 2012 Jan 5;119(1):7-15
references.pmid: 22021371
references.citation: J Clin Oncol. 2012 Apr 1;30(10):1030-3
references.pmid: 22370321
references.citation: N Engl J Med. 2012 May 10;366(19):1770-81
references.pmid: 22571201
references.citation: PLoS One. 2013 Aug 19;8(8):e72635
references.pmid: 23977334
references.citation: N Engl J Med. 2012 May 10;366(19):1759-69
references.pmid: 22571200
references.citation: Lancet Oncol. 2013 Oct;14(11):1055-1066
references.pmid: 24007748
references.citation: Nat Rev Cancer. 2012 Apr 12;12(5):335-48
references.pmid: 22495321
references.citation: N Engl J Med. 2014 Sep 4;371(10):906-17
references.pmid: 25184863
references.citation: Blood. 2012 Oct 4;120(14):2817-25
references.pmid: 22833546